Ultra-Committed
- - - To transform the lives of as many people living with rare diseases as possible, we dedicate ourselves every day to the development and delivery of treatments of rare diseases where none currently exist.
  - - Ultra-Committed
      Learn more
  - Ultra-committed
Research
- - - We develop therapies for rare and ultrarare genetic diseases by exploring an array of drug modalities to select the best treatment strategy for each genetic disease we are studying.
  - - Research
      Learn more
Medicines
Partnerships
Join Our Team
- - - We have built a talented team and a vibrant, people-first culture. We share a passion for helping those living with rare diseases.
  - - Join our team
      Learn More
  - Join Our Team
Newsroom
- - - Access news releases, presentations, and blog posts to follow the latest developments at Ultragenyx.
  - - Newsroom
      Learn More
  - Newsroom
Investors
- - Investor Relations

Release
details

Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)

December 4, 2013

Ultragenyx Announces Initiation of Phase 1/2 Study of Recombinant Human Beta-Glucuronidase (rhGUS) in Mucopolysaccharidosis Type 7 (MPS 7)